Mast Therapeutics, Inc. (NYSE: MSTX) today announced preliminary findings from a randomized, placebo-controlled, nonclinical study of vepoloxamer (MST-188) in a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE